Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation

Cancer Biology and Therapy

Volumn 13, Issue 10, 2012, Pages 956-966

  Runkle, Kristin B ^a   Meyerkord, Cheryl L ^b   Desai, Neelam V ^a   Takahashi, Yoshinori ^a   Wang, Hong Gang ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bif 1 endophilin B1; EGFR; Endocytosis; Migration; Rab7

Indexed keywords

A 1024; BIF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAB PROTEIN; RAB7 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL VACUOLE; CHEMOTAXIS; CONTROLLED STUDY; CYTOSKELETON; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVATION; HUMAN; INTERNALIZATION; LYSOSOME; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOTAXIS; CYTOSKELETON; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SPACE; PROTEIN TRANSPORT; PROTEOLYSIS; RAB GTP-BINDING PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPORT VESICLES;

EID: 84864538866     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20951     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Nanda R. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Semin Oncol 2011; 38:254-62; PMID:21421115; http://dx.doi.org/10.1053/j.seminoncol.2011.01.007.
3. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008; 359:2814-23; PMID:19109576; http://dx.doi.org/10.1056/NEJMra0805239.
4. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23:7350-60; PMID:16145060; http://dx.doi.org/10.1200/JCO.2005.03. 3845.
5. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003; 1:801-9; PMID:14517342.
6. Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 2002; 75:51-5.
7. Mesaki K, Tanabe K, Obayashi M, Oe N, Takei K. Fission of tubular endosomes triggers endosomal acidification and movement. PLoS One 2011; 6:19764; PMID:21572956; http://dx.doi.org/10.1371/journal.pone.0019764.
8. Huotari J, Helenius A. Endosome maturation. EMBO J 2011; 30:3481-500; PMID:21878991; http://dx.doi.org/10.1038/emboj.2011.286.
9. Ganley IG, Wong PM, Gammoh N, Jiang X. Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. Mol Cell 2011; 42:731-43; PMID:21700220; http://dx.doi.org/10.1016/j.molcel.2011.04.024.
10. Wang T, Ming Z, Xiaochun W, Hong W. Rab7: role of its protein interaction cascades in endo-lysosomal traffic. Cell Signal 2011; 23:516-21; PMID:20851765; http://dx.doi.org/10.1016/j.cellsig.2010.09.012.
11. Jordens I, Fernandez-Borja M, Marsman M, Dusseljee S, Janssen L, Calafat J, et al. The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. Curr Biol 2001; 11:1680-5; PMID:11696325; http://dx.doi.org/10.1016/S0960-9822(01)00531-0.
12. Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65:2993-5; PMID:15833821.
13. Sun-Wada GH, Wada Y, Futai M. Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell Struct Funct 2003; 28:455-63; PMID:14745137; http://dx.doi.org/10.1247/csf.28.455.
14. Roepstorff K, Grøvdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol 2008; 129:563-78; PMID:18288481; http://dx.doi.org/10.1007/ s00418-008-0401-3.
15. Cuddeback SM, Yamaguchi H, Komatsu K, Miyashita T, Yamada M, Wu C, et al. Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem 2001; 276:20559-65; PMID:11259440; http://dx.doi.org/10.1074/jbc.M101527200.
16. Pierrat B, Simonen M, Cueto M, Mestan J, Ferrigno P, Heim J. SH3GLB, a new endophilin-related protein family featuring an SH3 domain. Genomics 2001; 71:222-34; PMID:11161816; http://dx.doi.org/10.1006/geno.2000.6378.
17. Takahashi Y, Meyerkord CL, Wang HG. Bif-1/endophilin B1: a candidate for crescent driving force in autophagy. Cell Death Differ 2009; 16:947-55; PMID:19265852; http://dx.doi.org/10.1038/cdd.2009.19.
18. Lee JW, Jeong EG, Soung YH, Nam SW, Lee JY, Yoo NJ, et al. Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology 2006; 38:312-5; PMID:16916719; http://dx.doi.org/10.1080/00313020600820880.
19. Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Downregulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer 2008; 113:2665-70; PMID:18833585; http://dx.doi.org/10.1002/cncr.23892.
20. Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, et al. Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer 2008; 6:117-21; PMID:18824435; http://dx.doi.org/10.3816/CGC.2008.n.018.
21. Coppola D, Helm J, Ghayouri M, Malafa MP, Wang HG. Downregulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma. Pancreas 2011; 40:433-7; PMID:21283040; http://dx.doi.org/10.1097/MPA.0b013e318205eb03.
22. Kim SY, Oh YL, Kim KM, Jeong EG, Kim MS, Yoo NJ, et al. Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology 2008; 40:553-7; PMID:18752120; http://dx.doi.org/10.1080/00313020802320440.
23. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007; 9:1142-51; PMID:17891140; http://dx.doi.org/10.1038/ncb1634.
24. Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, et al. Novel breast cancer metastasis-associated proteins. J Proteome Res 2009; 8:583-94; PMID:19086899; http://dx.doi.org/10.1021/pr8007368.
25. Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987; 1:216-23; PMID:3502607; http://dx.doi.org/10.1210/mend-1-3-216.
26. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol) 2011; 23:587-600; PMID:21524569; http://dx.doi.org/10.1016/j.clon. 2011.03.013.
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-24; PMID:16049480; http://dx.doi.org/10.1038/nature03799.
28. Thoresen SB, Pedersen NM, Liestøl K, Stenmark H. A phosphatidylinositol-3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316:3368-78; PMID:20643123; http://dx.doi.org/10. 1016/j.yexcr.2010.07.008.
29. Zhang C, Li A, Zhang X, Xiao H. A novel TIP30 protein complex regulates EGF receptor signaling and endocytic degradation. J Biol Chem 2011; 286:9373-81; PMID:21252234; http://dx.doi.org/10.1074/jbc.M110.207720.
30. Wan J, Cheung AY, Fu WY, Wu C, Zhang M, Mobley WC, et al. Endophilin B1 as a novel regulator of nerve growth factor/TrkA trafficking and neurite outgrowth. J Neurosci 2008; 28:9002-12; PMID:18768694; http://dx.doi.org/10. 1523/JNEUROSCI.0767-08.2008.
31. Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B. Rab7: a key to lysosome biogenesis. Mol Biol Cell 2000; 11:467-80; PMID:10679007.
32. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291:113-35; PMID:10675719; http://dx.doi.org/10. 1016/S0009-8981(99)00224-7.
33. Wang W, Goswami S, Sahai E, Wyckoff JB, Segall JE, Condeelis JS. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 2005; 15:138-45; PMID:15752977; http://dx.doi.org/10.1016/j. tcb.2005.01.003.
34. Ringstad N, Nemoto Y, De Camilli P. The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. Proc Natl Acad Sci USA 1997; 94:8569-74; PMID:9238017; http://dx.doi.org/10.1073/pnas.94.16.8569.
35. Gad H, Ringstad N, Löw P, Kjaerulff O, Gustafsson J, Wenk M, et al. Fission and uncoating of synaptic clathrin-coated vesicles are perturbed by disruption of interactions with the SH3 domain of endophilin. Neuron 2000; 27:301-12; PMID:10985350; http://dx.doi.org/10.1016/S0896-6273(00)00038-6.
36. Rostovtseva TK, Boukari H, Antignani A, Shiu B, Banerjee S, Neutzner A, et al. Bax activates endophilin B1 oligomerization and lipid membrane vesiculation. J Biol Chem 2009; 284:34390-9; PMID:19805544; http://dx.doi.org/ 10.1074/jbc.M109.021873.
37. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008; 10:776-87; PMID:18552835; http://dx.doi.org/10.1038/ncb1740.
38. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 2005; 122:735-49; PMID:16143105; http://dx.doi.org/10.1016/j.cell.2005.06.043.
39. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425:145-50; PMID:9541025; http://dx.doi.org/10.1016/S0014-5793(98)00224-5.
40. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84:359-69; PMID:8608589; http://dx.doi.org/10. 1016/S0092-8674(00)81280-5.
41. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8:23; PMID:20822528; http://dx.doi.org/10.1186/1478- 811X-8-23.
42. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137:481-92; PMID:9128257; http://dx.doi.org/10.1083/jcb.137.2.481.
43. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003; 22:395-403; PMID:12884914; http://dx.doi.org/10.1023/A:1023781114568.